is being presented by Dr. Johann Proeve, Head of Global Data Management, with Bayer Healthcare and airs on Thursday, March 24th, 2011. For more details or to register, please visit our site at www.fxconferences.com
Off-shoring of certain activities related to the management of clinical trials has become commonplace in the pharmaceutical and biotechnology industry, and one of the functions most affected has been clinical data management (CDM). The main contributors for off-shoring CDM are the fixed costs, lower salaries in low-cost countries and CDM being viewed as a non-core competency in the industry.
But is off-shoring really the easy solution it might appear to be when faced with the rising cost of conducting clinical research? Certainly, off-shoring of CDM is associated with certain risks, including high staff turnover, required overhead for the management of the processes, availability of knowledgeable staff for health authority inspections and the eventual erosion of the cost advantage compared to Western countries.
This audio conference addresses the main drivers and risks associated with the off-shoring of CDM, and looks at the various ways in which CDM can contribute and thereby justify its existence.
